Clinical trial of epirubicin chitosan microspheres combined with oxaliplatin injection in the treatment of primary hepatic carcinoma
10.13699/j.cnki.1001-6821.2018.10.005
- VernacularTitle:表柔比星壳聚糖微球联合奥沙利铂注射剂治疗原发性肝癌的临床研究
- Author:
Hai-Xing SHEN
1
;
Kai LI
Author Information
1. 慈溪市人民医院普外科
- Keywords:
epirubicin chitosan microsphere;
oxaliplatin injection;
primary hepatic carcinoma;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(10):1147-1150
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of epirubicin chitosan microspheres combined with oxaliplatin injection in the treatment of primary hepatic carcinoma.Methods Seventy patients with primary hepatic carcinoma were randomly divided into control and treatment groups with 35 cases per group.Control group was given 130 mg · m-2 oxaliplatin,once a week,slow perfusion.Treatment group was treated with epirubicin chitosan microspheres 30 mg per time,once a week,perfusion on the basis of control group.Two groups were treated for 2 cycles with 4 weeks per cycle.The clinical efficacy,liver function,alpha fetal protein,glycoprotein antigen 199,glutamate transferase (GGT),and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates of treatment and control groups were 77.14％ (27 cases / 35 cases) and 54.29％ (19 cases /35 cases) with significant difference (P ＜ 0.05).After treatment,the main indexes in control and treatment groups were compared:alanine transaminase were (51.49 ± 5.79) and (33.26 ± 4.43) U · L-1,aspartate aminotransferase were (56.17 ± 6.72) and (41.39 ± 4.63) U · L-1,alpha fetal protein were (139.20 ± 16.04) and (112.15 ± 13.32) ng · mL-1,glycoprotein antigen 199 were (63.49 ± 8.05)and (48.93 ±6.46) U · L-1,GGT were(120.83 ± 14.31) and (103.49 ± 12.18) U · L-1,the differences were statistically significant (all P ＜ 0.05).The adverse drug reactions of treatment group were digestive response,low-grade fever and transaminase raise,which in control group were digestive response,low-grade fever,abdomen ache and jaundice.The total incidences of adverse drug reactions in treatment and control groups were 8.57％ and 31.42％ with significant difference (P ＜ 0.05).Conclusion Epirubicin chitosan microspheres combined with oxaliplatin injection have a definitive clinical and safety in the treatment of primary hepatic carcinoma.
